Skip to main content
. 2025 Jan 30;37(1):48–65. doi: 10.21147/j.issn.1000-9604.2025.01.04

Table 1. Patient characteristics of FUSCC HR+HER2 breast cancer cohort among recurrence group.

Variables n (%) P
Overall
(N=314)
No relapse
(N=201)
Primary
resistant (N=49)
Secondary
resistant (N=41)
Endocrine
sensitive (N=23)
FUSCC, Fudan University Shanghai Cancer Center; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; IDC, infiltrating ductal carcinoma; HER2-low, HER2 immunohistochemistry 1+ or HER2 IHC 2+ with in situ hybridization (−); LVI, lymphovascular invasion; SNF, similarity network fusion.
Age (year) 0.006
 ≤50 142 (45.2) 87 (43.3) 29 (59.2) 22 (53.7) 4 (17.4)
 >50 172 (54.8) 114 (56.7) 20 (40.8) 19 (46.3) 19 (82.6)
Menopause 0.121
 Premenopause 137 (43.6) 84 (41.8) 25 (51.0) 22 (53.7) 6 (26.1)
 Postmenopausal 176 (56.1) 117 (58.2) 24 (49.0) 18 (43.9) 17 (73.9)
 Unknown 1 (0.3) 0 (0) 0 (0) 1 (2.4) 0 (0)
Laterality 0.625
 Left 166 (52.9) 104 (51.7) 30 (61.2) 21 (51.2) 11 (47.8)
 Right 148 (47.1) 97 (48.3) 19 (38.8) 20 (48.8) 12 (52.2)
Histology 0.201
 IDC 293 (93.3) 184 (91.5) 47 (95.9) 41 (100) 21 (91.3)
 Others 21 (6.7) 17 (8.5) 2 (4.1) 0 (0) 2 (8.7)
pT <0.001
 pT1 132 (42.0) 106 (52.7) 14 (28.6) 10 (24.4) 2 (8.7)
 pT2 175 (55.7) 93 (46.3) 32 (65.3) 31 (75.6) 19 (82.6)
 pT3 6 (1.9) 2 (1.0) 2 (4.1) 0 (0) 2 (8.7)
 Unknown 1 (0.3) 0 (0) 1 (2.0) 0 (0) 0 (0)
pN <0.001
 pN0 125 (39.8) 103 (51.2) 8 (16.3) 11 (26.8) 3 (13.0)
 pN1 94 (29.9) 59 (29.4) 10 (20.4) 16 (39.0) 9 (39.1)
 pN2 52 (16.6) 29 (14.4) 14 (28.6) 5 (12.2) 4 (17.4)
 pN3 43 (13.7) 10 (5.0) 17 (34.7) 9 (22.0) 7 (30.4)
Grade 0.216
 Grade I 3 (1.0) 3 (1.5) 0 (0) 0 (0) 0 (0)
 Grade II 195 (62.1) 135 (67.2) 26 (53.1) 23 (56.1) 11 (47.8)
 Grade III 88 (28.0) 49 (24.4) 17 (34.7) 12 (29.3) 10 (43.5)
 Unknown 28 (8.9) 14 (7.0) 6 (12.2) 6 (14.6) 2 (8.7)
HER2 status 0.060
 HER2-0 59 (18.8) 31 (15.4) 15 (30.6) 9 (22.0) 4 (17.4)
 HER2-low 237 (75.5) 163 (81.1) 34 (69.4) 32 (78.0) 8 (34.8)
 Unknown 18 (5.7) 7 (3.5) 0 (0) 0 (0) 11 (47.8)
ER status 0.029
 ER>10% 266 (84.7) 201 (100) 24 (49.0) 22 (53.7) 19 (82.6)
 ER 1%−10% 3 (1.0) 0 (0) 2 (4.1) 0 (0) 1 (4.3)
 Unknown 45 (14.3) 0 (0) 23 (46.9) 19 (46.3) 3 (13.0)
PR status 0.192
 PR>10% 216 (68.8) 164 (81.6) 20 (40.8) 17 (41.5) 15 (65.2)
 PR 1%−10% 36 (11.5) 21 (10.4) 6 (12.2) 4 (9.8) 5 (21.7)
 Unknown 62 (19.7) 16 (8.0) 23 (46.9) 20 (48.8) 3 (13.0)
Ki-67 status 0.528
 Ki-67>25% 152 (48.4) 96 (47.8) 24 (49) 19 (46.3) 13 (56.5)
 Ki-67≤25% 155 (49.4) 105 (52.2) 21 (42.9) 20 (48.8) 9 (39.1)
 Unknown 7 (2.2) 0 (0) 4 (8.2) 2 (4.9) 1 (4.3)
LVI <0.001
 Yes 166 (52.9) 84 (41.8) 39 (79.6) 27 (65.9) 16 (69.6)
 No 146 (46.5) 116 (57.7) 10 (20.4) 13 (31.7) 7 (30.4)
 Unknown 2 (0.6) 1 (0.5) 0 (0) 1 (2.4) 0 (0)
SNF subtype <0.001
 SNF1 50 (15.9) 36 (17.9) 5 (10.2) 7 (17.1) 2 (8.7)
 SNF2 51 (16.2) 29 (14.4) 14 (28.6) 3 (7.3) 5 (21.7)
 SNF3 71 (22.6) 40 (19.9) 10 (20.4) 13 (31.7) 8 (34.8)
 SNF4 35 (11.1) 13 (6.5) 12 (24.5) 8 (19.5) 2 (8.7)
 Unknown 107 (34.1) 83 (41.3) 8 (16.3) 10 (24.4) 6 (26.1)
PAM50 subtype <0.001
 Basal 12 (3.8) 8 (4.0) 1 (2.0) 3 (7.3) 0 (0)
 HER2 13 (4.1) 8 (4.0) 2 (4.1) 1 (2.4) 2 (8.7)
 LumA 98 (31.2) 86 (42.8) 4 (8.2) 4 (9.8) 4 (17.4)
 LumB 99 (31.5) 81 (40.3) 3 (6.1) 6 (14.6) 9 (39.1)
 Normal 17 (5.4) 12 (6.0) 2 (4.1) 3 (7.3) 0 (0)
 Unknown 75 (23.9) 6 (3.0) 37 (75.5) 24 (58.5) 8 (34.8)